share_log

Merck & Co | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers

Merck & Co | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers

默沙东 | S-3ASR:“知名成熟发行人”证券注册声明
SEC announcement ·  03/19 16:32
Moomoo AI 已提取核心信息
Merck & Co., Inc., a leading global healthcare company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on March 19, 2024. The registration statement pertains to the issuance of debt securities, which may be offered and sold from time to time by Merck. The company has appointed U.S. Bank Trust National Association as the trustee for the debt securities. The registration statement includes a prospectus that provides detailed information about the debt securities, including their potential form, terms, and conditions. Merck & Co. has also outlined the plan of distribution for the debt securities, which may involve underwriters, dealers, agents, or direct sales to investors. The company has made provisions for indemnification of directors and officers, and...Show More
Merck & Co., Inc., a leading global healthcare company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on March 19, 2024. The registration statement pertains to the issuance of debt securities, which may be offered and sold from time to time by Merck. The company has appointed U.S. Bank Trust National Association as the trustee for the debt securities. The registration statement includes a prospectus that provides detailed information about the debt securities, including their potential form, terms, and conditions. Merck & Co. has also outlined the plan of distribution for the debt securities, which may involve underwriters, dealers, agents, or direct sales to investors. The company has made provisions for indemnification of directors and officers, and the registration statement includes the necessary legal opinions and consents. The debt securities will be a new issue with no established trading market prior to their issuance, and Merck & Co. may choose to list the securities on an exchange. The registration statement also includes undertakings by Merck & Co. to provide updates and post-effective amendments as required by the SEC.
全球领先的医疗保健公司默沙东公司已于2024年3月19日向美国证券交易委员会(SEC)提交了S-3表格注册声明。注册声明涉及债务证券的发行,默沙东可以不时发行和出售债券。该公司已任命美国银行信托全国协会为债务证券的受托人。注册声明包括一份招股说明书,其中提供了有关债务证券的详细信息,包括其潜在形式、条款和条件。默沙东公司还概述了债务证券的分配计划,其中可能涉及承销商、交易商、代理或直接向投资者销售。公司已制定了对董事和高级管理人员进行赔偿的规定,注册声明包括必要的法律意见和同意。债务证券将是新发行的债券,在发行前尚未建立交易市场,默沙东公司可能会选择在交易所上市。注册声明还包括默沙东公司承诺按照美国证券交易委员会的要求提供更新和生效后的修订。
全球领先的医疗保健公司默沙东公司已于2024年3月19日向美国证券交易委员会(SEC)提交了S-3表格注册声明。注册声明涉及债务证券的发行,默沙东可以不时发行和出售债券。该公司已任命美国银行信托全国协会为债务证券的受托人。注册声明包括一份招股说明书,其中提供了有关债务证券的详细信息,包括其潜在形式、条款和条件。默沙东公司还概述了债务证券的分配计划,其中可能涉及承销商、交易商、代理或直接向投资者销售。公司已制定了对董事和高级管理人员进行赔偿的规定,注册声明包括必要的法律意见和同意。债务证券将是新发行的债券,在发行前尚未建立交易市场,默沙东公司可能会选择在交易所上市。注册声明还包括默沙东公司承诺按照美国证券交易委员会的要求提供更新和生效后的修订。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息